Cancers, Vol. 11, Pages 1798: Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis

In conclusion, TMB may be an effective biomarker to predict survival in patients undergoing ICI treatment. The role of TMB in identifying patient groups who may benefit from ICIs should be determined in future randomized controlled trials.

Source: Cancers - November 14, 2019 Category: Cancer & Oncology Authors: Jong Yeob Kim Andreas Kronbichler Michael Eisenhut Sung Hwi Hong Hans J. van der Vliet Jeonghyun Kang Jae Il Shin Gabriele Gamerith Tags: Article Source Type: research